Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers

被引:105
|
作者
Mulvihill, John J. E. [1 ,2 ,3 ,4 ]
Cunnane, Eoghan M. [5 ]
Ross, Aisling M. [1 ,4 ]
Duskey, Jason T. [6 ]
Tosi, Giovanni [6 ]
Grabrucker, Andreas M. [1 ,2 ,3 ,7 ]
机构
[1] Univ Limerick, Bernal Inst, Limerick V94 T9PX, Ireland
[2] Univ Limerick, Hlth Res Inst HRI, Limerick V94 T9PX, Ireland
[3] Univ Limerick, Synth & Solid State Pharmaceut Ctr, Limerick V94 T9PX, Ireland
[4] Univ Limerick, Sch Engn, Limerick V94 T9PX, Ireland
[5] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15260 USA
[6] Univ Modena & Reggio Emilia, Dept Life Sci, NanoTech Lab, I-41124 Modena, Italy
[7] Univ Limerick, Dept Biol Sci, Limerick V94 T9PX, Ireland
关键词
BBB; brain; drug targeting; exosomes; liposomes nano; nanomedicines; nanoparticles; PLGA; theranostics; ENDOTHELIAL-CELLS; PROTEIN CORONA; NANOPARTICLES; NANOMEDICINE; TRANSCYTOSIS; NANOTECHNOLOGY; PERSPECTIVES; TOXICITY; THERAPY; MODEL;
D O I
10.2217/nnm-2019-0367
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The blood-brain barrier (BBB) has a significant contribution to homeostasis and protection of the CNS. However, it also limits the crossing of therapeutics and thereby complicates the treatment of CNS disorders. To overcome this limitation, the use of nanocarriers for drug delivery across the BBB has recently been exploited. Nanocarriers can utilize different physiological mechanisms for drug delivery across the BBB and can be modified to achieve the desired kinetics and efficacy. Consequentially, several nanocarriers have been reported to act as functional nanomedicines in preclinical studies using animal models for human diseases. Given the rapid development of novel nanocarriers, this review provides a comprehensive insight into the most recent advancements made in nanocarrier-based drug delivery to the CNS, such as the development of multifunctional nanomedicines and theranostics.
引用
收藏
页码:205 / 214
页数:10
相关论文
共 50 条
  • [41] Drug transport across the blood-brain barrier
    Fricker, G
    PHARMACOKINETIC CHALLENGES IN DRUG DISCOVERY, 2002, 37 : 139 - 154
  • [42] Drug transport across the blood-brain barrier
    Pardridge, William M.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2012, 32 (11): : 1959 - 1972
  • [43] Promoting Drug Delivery to the Brain by Modulating the Transcytosis Process across the Blood-Brain Barrier
    Zhang, Li
    Mao, Zhennan
    Li, Weibin
    Chi, Siyu
    Cheng, Hemei
    Wang, Zijun
    Wang, Caixia
    Liu, Zhihong
    ACS APPLIED MATERIALS & INTERFACES, 2025,
  • [44] Established and Emerging Strategies for Drug Delivery Across the Blood-Brain Barrier in Brain Cancer
    Parodi, Alessandro
    Rudzinska, Magdalena
    Deviatkin, Andrei A.
    Soond, Surinder M.
    Baldin, Alexey, V
    Zamyatnin, Andrey A., Jr.
    PHARMACEUTICS, 2019, 11 (05):
  • [45] Modulation of the Blood-Brain Barrier for Drug Delivery to Brain
    Han, Liang
    PHARMACEUTICS, 2021, 13 (12)
  • [46] Advanced Blood-Brain Barrier Drug Delivery
    Pardridge, William M.
    PHARMACEUTICS, 2023, 15 (01)
  • [47] Drug delivery to brain via the blood-brain barrier
    Scherrmann, JM
    VASCULAR PHARMACOLOGY, 2002, 38 (06) : 349 - 354
  • [48] CSF, blood-brain barrier, and brain drug delivery
    Pardridge, William M.
    EXPERT OPINION ON DRUG DELIVERY, 2016, 13 (07) : 963 - 975
  • [49] Advances in microphysiological blood-brain barrier (BBB) models towards drug delivery
    Lee, Caleb S.
    Leong, Kam W.
    CURRENT OPINION IN BIOTECHNOLOGY, 2020, 66 : 78 - 87
  • [50] Breaching the Blood-Brain Barrier for Drug Delivery
    Bell, Robert D.
    Ehlers, Michael D.
    NEURON, 2014, 81 (01) : 1 - 3